Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $492.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +31 vs. previous quarter
- 139
- 13F valueReported value at the end of Q2 2026
- $492.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CABA, Q2 2026
No superinvestor reported holding CABA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cabaletta Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Chang David J.Chief Medical Officer | PPurchase | +8.80K | $2.26 | +$19.9K | New position8.80K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Binder GwendolynPresident, Science & Tech. | PPurchase | +11.3K | $2.19 | +$24.8K | +56.6%31.3K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Tomasello ShawnDirector | PPurchase | +22.7K | $2.21 | +$50.2K | New position22.7K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Gavel SteveChief Commercial Officer | PPurchase | +22.2K | $2.27 | +$50.3K | New position22.2K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Bollard CatherineDirector | PPurchase | +4.41K | $2.27 | +$10.0K | +440.5%5.41K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Nichtberger StevenPresident & CEO | PPurchase | +45.0K | $2.24 | +$100.8K | +4.6%1.03M after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Simon MarkDirector | PPurchase | +11.1K | $2.28 | +$25.2K | +8.1%147.2K after | |
| Jan 21, 2026 (view filing) | Jan 21 | Same day | Gerard MichaelGeneral Counsel | PPurchase | +6.60K | $2.27 | +$15.0K | New position6.60K after | |
| Jan 19, 2024 (view filing) | Jan 19 | Same day | Binder GwendolynSee Remarks | SSale | −11.0K | $19.59 | −$215.5K | −35.5%20.0K after | 2 lots |
| Dec 19, 2023 (view filing) | Dec 19 | Same day | Binder GwendolynSee Remarks | SSale | −11.0K | $21.89 | −$240.8K | −35.5%20.0K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cabaletta Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jennison Associates LLC | 20,033,730 | $62.3M | 0.04% | +11,063,152+123.3% | Added |
| T. Rowe Price Investment Management, Inc. | 18,869,907 | $58.7M | 0.04% | +7,789,902+70.3% | Added |
| Bain Capital Life Sciences Investors, LLC | 17,241,445 | $53.6M | 3.19% | +7,564,320+78.2% | Added |
| BlackRock, Inc. | 10,754,701 | $33.4M | 0.00% | +8,381,698+353.2% | Added |
| Adage Capital Partners GP, L.L.C. | 9,174,758 | $28.5M | 0.04% | +345,000+3.9% | Added |
| State Street Corp | 7,839,305 | $24.4M | 0.00% | +7,369,327+1,568.0% | Added |
| Vanguard Capital Management LLC | 7,227,018 | $22.5M | 0.00% | +3,198,027+79.4% | Added |
| Cormorant Asset Management, LP | 5,000,000 | $15.6M | 0.80% | −500,000−9.1% | Reduced |
| Price T Rowe Associates Inc | 4,418,674 | $13.7M | 0.00% | +3,976,397+899.1% | Added |
| Woodline Partners LP | 4,200,142 | $13.1M | 0.04% | +2,949,900+235.9% | Added |